Exposure to biologic therapies during conception and pregnancy: a systematic review.

about

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review.

P2860

Q54214331-6F29E6CF-3ADA-4570-8E67-A659A58F5583

P2860

Exposure to biologic therapies during conception and pregnancy: a systematic review.

Item

http://www.wikidata.org/entity/Q39441592

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Exposure to biologic therapies during conception and pregnancy: a systematic review.

@en

Exposure to biologic therapies during conception and pregnancy: a systematic review.

@nl

type

Item

label

Exposure to biologic therapies during conception and pregnancy: a systematic review.

@en

Exposure to biologic therapies during conception and pregnancy: a systematic review.

@nl

prefLabel

Exposure to biologic therapies during conception and pregnancy: a systematic review.

@en

Exposure to biologic therapies during conception and pregnancy: a systematic review.

@nl

P1476

Exposure to biological therapies during conception and pregnancy: a systematic review

@en

P2093

A D Burden

http://www.w3.org/2001/XMLSchema#string

C Nelson-Piercy

http://www.w3.org/2001/XMLSchema#string

E Pottinger

http://www.w3.org/2001/XMLSchema#string

L S Exton

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit?

Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy

Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium.

Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy.

A meta-analysis on the influence of inflammatory bowel disease on pregnancy.

Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.

A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.

P304

95-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.15802

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P50

Catherine H Smith

Richard Woolf

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28718898

http://www.w3.org/2001/XMLSchema#string

Exposure to biologic therapies during conception and pregnancy: a systematic review.

about

P2860

P2860

Exposure to biologic therapies during conception and pregnancy: a systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698